All In Biotech

Drug Trial Radar · NCT06894511

An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC

A Phase II, Open-label, Multi-Center, Randomized Study of Combination of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) and Androgen Receptor Pathway Inhibitor (ARPI) vs. Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in First-line Treatment of Patients With Prostate-Specific Membrane Antigen (PSMA)-Positive Progressive Metastatic Castration Resistant Prostate Cancer (mCRPC)

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

7

Actual

Start

Sep 11, 2025

Primary completion

Nov 17, 2026

Study completion Nov 17, 2026

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Mar 25, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess safety of combination of AAA617 (administered for 6 cycles at a dose of 7.4 GBq (200 mCi) +/- 10%) and ARPI and AAA617 alone in PSMA-positive mCRPC patients who were previously treated and progressed on ARPI in the biochemical recurrence (BCR)-non metastatic hormone sensitive prostate cancer (mHSPC), mHSPC, or non-metastatic Castration Resistant Prostate Cancer (nmCRPC) setting and have not previously received a taxane-containing regimen in the metastic castrate resistant prostate cancer (mCRPC) setting.

Conditions

  • Metastatic Castration Resistant Prostate Cancer (mCRPC)

Interventions

  • AAA617Drug

    Dose formulation: open-label vial Dose level: 7.4 GBq (200 mCi) ± 10% Once, every 6 weeks for 6 cycles, intravenous administration

  • ARPI: AbirateroneDrug

    Dose formulation: tablet/capsule Dose level: 160 mg (four 40 mg soft capsules or four 40 mg tablets or two 80 mg tablets) as a single daily dose, oral administration

  • ARPI: EnzalutamideDrug

    Dose formulation: tablet Dose level: 1000 mg daily (two 500 mg tablets or four 250 mg tablets as a single daily dose together with 5 mg oral prednisone 2 times a day, oral administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety: Number of participants with adverse events (AEs) and serious adverse events (SAEs)Time frame: up to end of study, approx. 1.5 years

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Cancer And Blood Spclsts of AZ

    Casa Grande, Arizona

  • Arizona Center for Cancer Care

    Gilbert, Arizona

  • Hoag Memorial Hospital Presbyterian

    Newport Beach, California

  • Cancer Specialists of North Florida

    Jacksonville, Florida

  • Urology Cancer Center PC

    Omaha, Nebraska

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.